ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Why Amazon Refuses to Wear Purple Lanyards in Vegas1 Apr 2015, 7:00 amAbout 1,300 people from the online retail industry are in Las Vegas this week for the annual Catalyst Americas conference. Amazon acquired Quidsi in 2010 for $550 million, and Lore stayed on for more than two years.
First Week of ARIA November 20th Options Trading25 Mar 2015, 10:31 amFirst Week of ARIA November 20th Options Trading
Biogen Hits High As Alzheimer's Drug Impressive In Trial20 Mar 2015, 4:09 pmBiogen Idec wowed the medical community and investors with its much-anticipated Alzheimer's disease drug results Friday, sending its stock to a new high before closing up 9.8% to 475.98. At a medical conference ...
Health Exchange: Street gushes over Alzheimer’s drug, but some worry about overreaction20 Mar 2015, 11:25 amAnalysts split in their reactions to Biogen Idec’s report of test results for its new Alzheimer’s drug.
Biogen Alzheimer's drug shows promise, shares surge20 Mar 2015, 3:46 amA Biogen Alzheimer's drug showed reductions in levels of the amyloid plaques and a significant slowing of the disease's hallmark cognitive declines.
Biogen Alzheimer's drug tops views20 Mar 2015, 3:43 amA Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.
Does This ARIAD Pharmaceuticals, Inc. (ARIA) Rally Have Legs?16 Mar 2015, 11:51 amAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) is following a number of sector peers higher this afternoon, in what's turning out to be a ... ( Read More )
Critical Alerts For TASER International, Cisco Systems, Netflix, Ubiquiti Networks, Ariad Pharmaceuticals, Zoe's ...10 Mar 2015, 7:45 amCHICAGO, March 10, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TASR, CSCO, NFLX, UBNT, ARIA, ZOES, OPK, GRPN, AFOP and SLW.To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the...
Tuesday 2/17 Insider Buying Report: ARIA, DAL9 Mar 2015, 7:50 amAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
'Fast Money' Recap: Should You Buy European or U.S. Stocks?8 Mar 2015, 9:37 amNEW YORK ( TheStreet) -- In the past five weeks, $15 billion has flowed into European stocks, begging the question of whether one continent is better than the other at this point in time. The CNBC "Fast Money" panel sought to answer that question and more Friday. Brian Kelly, founder of Brian Kelly Capital, said given a choice between the two regions, he would go with European stocks. But he ...